Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amg 193 + sotorasib
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**AMG 193 + sotorasib** is an investigational combination therapy comprised of two small molecule drugs: **AMG 193**, a novel orally bioavailable MTA-cooperative PRMT5 inhibitor, and **sotorasib (AMG-510, Lumakras)**, a first-in-class covalent KRAS G12C inhibitor. AMG 193 selectively targets PRMT5 in MTAP-deleted tumor cells, causing DNA damage, cell cycle arrest, and apoptosis via inhibition of symmetric dimethylarginine (SDMA) formation. Sotorasib irreversibly inhibits the mutant KRAS G12C protein, preventing oncogenic signaling. This combination has shown synergistic antitumor effects in preclinical models and is being evaluated in clinical trials for advanced solid tumors, particularly those with MTAP-deletion and KRAS G12C mutations[1][2][9]. Both drugs are developed by Amgen.
- Brand names
- LumakrasLumykras
- Other names
- amg-193 + sotorasib
02
Targets
PRMT5 (Protein arginine N-methyltransferase 5)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on amg 193 + sotorasib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amg 193 + sotorasib.